A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2015
Price : $35 *
At a glance
- Drugs Centanafadine (Primary) ; Dexamfetamine; Lisdexamfetamine
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacodynamics
- Sponsors Neurovance
- 13 Aug 2014 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 16 Jun 2014 Status changed from planning to recruiting; according to ClinicalTrials.gov record.
- 07 Apr 2014 New trial record